| Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 19922961 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of the study was to investigate the effects of rosiglitazone and/or exercise training on novel cardiovascular risk factors in patients with type 2 diabetes mellitus. One hundred overweight/obese type 2 diabetes mellitus patients, with inadequate glycemic control (hemoglobin A(1c) >7%) despite combined treatment with gliclazide plus metformin, were randomized using a 2 x 2 factorial design to 4 equivalent (n = 25) groups, as follows: (1) CO: maintenance of habitual activities, (2) RSG: add-on therapy with rosiglitazone (8 mg/d), (3) EX: adjunctive exercise training, and (4) RSG + EX: supplementary administration of rosiglitazone (8 mg/d) plus exercise training. No participant had diabetic vascular complications or was receiving lipid-lowering therapy. Anthropometric parameters, cardiorespiratory capacity, glycemic and lipid profile, apolipoprotein (apo) A-I, apo B, interleukin (IL)-10, IL-18, insulin resistance, and blood pressure were measured before and after 12 months of intervention (P < .05). Both RSG and EX groups significantly reduced glycemic indexes, insulin resistance, blood pressure, and IL-18, whereas they significantly increased high-density lipoprotein, cardiorespiratory capacity, and IL-10, compared with CO group (P < .05). Besides this, exercise-treated patients conferred a remarkable down-regulation in the rest of lipid parameters (total cholesterol, low-density lipoprotein cholesterol, triglycerides, apo B) and body fat content (P < .05) in comparison with CO group. On the other hand, RSG group rather than CO group considerably increased apo A-I levels and body mass index (P < .05). Notably, the combined treatment group yielded pronounced beneficial changes in glycemic indexes, lipid profile, insulin resistance, blood pressure, IL-10, IL-18, apo A-I, and apo B (vs CO group, P < .05). Furthermore, the addition of exercise to rosiglitazone treatment counteracted the drug-related negative effects on body weight, low-density lipoprotein, and total cholesterol. Rosiglitazone plus exercise training elicited additive effects on body composition, glycemic control, and traditional and novel cardiovascular risk factors in type 2 diabetes mellitus patients, indicating complementary effects. |
| | |
Authors:
|
Nikolaos P E Kadoglou; Fotios Iliadis; Nikolaos Sailer; Zoi Athanasiadou; Ioulia Vitta; Alikistis Kapelouzou; Panayotis E Karayannacos; Christos D Liapis; Miltiadis Alevizos; Nikoletta Angelopoulou; Ioannis S Vrabas |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2009-11-18 |
Journal Detail:
|
Title: Metabolism: clinical and experimental Volume: 59 ISSN: 1532-8600 ISO Abbreviation: Metab. Clin. Exp. Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-03-22 Completed Date: 2010-04-07 Revised Date: 2010-06-07 |
Medline Journal Info:
|
Nlm Unique ID: 0375267 Medline TA: Metabolism Country: United States |
Other Details:
|
Languages: eng Pagination: 599-607 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
1st Department of Internal Medicine, "Hippokratio" General Hospital of Thessaloniki, Greece. nikoskad@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Body Composition C-Reactive Protein / analysis Cardiovascular Diseases / prevention & control* Diabetes Mellitus, Type 2 / complications* Exercise* Female Hemoglobin A, Glycosylated / analysis Humans Hypoglycemic Agents / pharmacology* Insulin Resistance Lipoproteins, LDL / blood Male Middle Aged Risk Factors Thiazolidinediones / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Lipoproteins, LDL; 0/Thiazolidinediones; 0/hemoglobin A1c protein, human; 122320-73-4/rosiglitazone; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Growth and maturation of the cases of congenital hypothyroidism detected by the neonatal screening p...
Next Document: Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal...